KLP Kapitalforvaltning AS Has $57.90 Million Stake in Thermo Fisher Scientific Inc. $TMO

Key Points

• KLP Kapitalforvaltning AS increased its stake in Thermo Fisher Scientific Inc. by 4.1% during Q2, now holding shares valued at $57.9 million.
• The company recently reported a quarterly EPS of $5.36, exceeding analysts' expectations, with a revenue increase of 2.9% year-over-year.
• Thermo Fisher Scientific announced a quarterly dividend of $0.43 per share, with an annualized yield of 0.3%, to be paid on October 15th to shareholders of record.

KLP Kapitalforvaltning AS increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 4.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 142,683 shares of the medical research company's stock after acquiring an additional 5,600 shares during the period. KLP Kapitalforvaltning AS's holdings in Thermo Fisher Scientific were worth $57,904,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of TMO. CBIZ Investment Advisory Services LLC grew its holdings in shares of Thermo Fisher Scientific by 137.5% during the first quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company's stock worth $28,000 after purchasing an additional 33 shares during the last quarter. Anderson Financial Strategies LLC bought a new position in shares of Thermo Fisher Scientific in the first quarter valued at about $30,000. Keystone Global Partners LLC bought a new stake in Thermo Fisher Scientific during the 1st quarter worth about $31,000. DiNuzzo Private Wealth Inc. increased its position in Thermo Fisher Scientific by 406.7% in the 2nd quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company's stock valued at $31,000 after acquiring an additional 61 shares in the last quarter. Finally, HighMark Wealth Management LLC raised its stake in shares of Thermo Fisher Scientific by 140.6% in the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company's stock worth $31,000 after acquiring an additional 45 shares during the last quarter. Institutional investors own 89.23% of the company's stock.

Insiders Place Their Bets

In other Thermo Fisher Scientific news, CAO Joseph R. Holmes sold 385 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 29th. The stock was sold at an average price of $492.63, for a total transaction of $189,662.55. Following the transaction, the chief accounting officer directly owned 2,319 shares in the company, valued at approximately $1,142,408.97. The trade was a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $479.98, for a total value of $191,992.00. Following the completion of the sale, the executive vice president owned 22,367 shares of the company's stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 30,066 shares of company stock worth $14,182,963. Company insiders own 0.33% of the company's stock.

Thermo Fisher Scientific Stock Up 0.2%

Shares of Thermo Fisher Scientific stock opened at $544.44 on Tuesday. The business has a fifty day simple moving average of $483.77 and a 200 day simple moving average of $446.95. The stock has a market cap of $205.59 billion, a PE ratio of 31.49, a price-to-earnings-growth ratio of 2.95 and a beta of 0.77. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $610.97.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.22 by $0.14. The firm had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The company's revenue was up 2.9% compared to the same quarter last year. During the same quarter last year, the business earned $5.37 earnings per share. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio is presently 9.95%.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. Raymond James Financial reissued an "outperform" rating and set a $535.00 price target (up from $525.00) on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research report on Thursday, July 24th. UBS Group lifted their target price on Thermo Fisher Scientific from $460.00 to $500.00 and gave the company a "neutral" rating in a research note on Thursday, July 24th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Thermo Fisher Scientific in a research note on Saturday, September 27th. Finally, Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research report on Saturday. Fifteen investment analysts have rated the stock with a Buy rating and six have given a Hold rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $585.37.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.